title: Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.
abstract: Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.
authors.affiliation: Department of Medicine, University of California Center for the Health Sciences, Los Angeles 90024, USA.
authors.forename: I J
authors.initials: IJ
authors.lastname: Chopra
authors.forename: A J
authors.initials: AJ
authors.lastname: van Herle
authors.forename: S G
authors.initials: SG
authors.lastname: Korenman
authors.forename: S
authors.initials: S
authors.lastname: Viosca
authors.forename: S
authors.initials: S
authors.lastname: Younai
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007487:Ipodate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013961:Thyroid Gland / Q000276:immunology / Q000378:metabolism; D013968:Thyroiditis, Subacute / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000097:blood*; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood*
chemical_list: D001323:Autoantibodies; D014284:Triiodothyronine; D013972:Thyrotropin; D007487:Ipodate; D013974:Thyroxine